About ProteoGenix
ProteoGenix is a company based in Schiltigheim (France) founded in 2003. ProteoGenix has raised $35.23 million across 8 funding rounds from investors including TPG, New Leaf Venture Partners and Burrill and Company. The company has 7 employees. ProteoGenix offers products and services including Custom Antibody Development, Custom Protein Expression, Peptide Synthesis, and XtenCHO Race Starter Kit. ProteoGenix operates in a competitive market with competitors including Amyris, Syngenta, AskBio, Somalogic and Ginkgo Bioworks, among others.
- Headquarter Schiltigheim, France
- Employees 7
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website proteogenix.science
- Social LinkedIn X Facebook
- Legal Name Proteogenex, Inc.
- Total Equity Funding$35.23M (USD)
in 8 rounds
- Latest Funding Round$4M (USD), Debt – Conventional
Apr 2010
- InvestorsTPG
& 2 more
- Employee Count7
Products & Services of ProteoGenix
ProteoGenix offers a comprehensive portfolio of products and services, including Custom Antibody Development, Custom Protein Expression, Peptide Synthesis, and XtenCHO Race Starter Kit.
Service for developing and producing custom antibodies for research.
Expression of proteins in various systems for applications.
Synthesis and modification of peptides for scientific use.
Kit for transient expression in mammalian cells.
Funding Insights of ProteoGenix
ProteoGenix has successfully raised a total of $35.23M across 8 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $4 million completed in April 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $35.23M
- Total Rounds 8
- Last Round Debt – Conventional — $4M
- First Round $1.27M
(Aug 2002)
- Investors Count 3
All 8 funding rounds of ProteoGenix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2010 | $4M | Debt – Conventional | – | – | – |
| Aug 2009 | $4M | Debt – Conventional | – | – | – |
| Jul 2008 | $8M | Series B | – | – | – |
| Jan 2008 | $2M | Series B | – | – | – |
| Jan 2008 | $2M | Series B | – | – | – |
| Mar 2007 | $20M | Series B | – | – | |
| Sep 2003 | $1.97M | Seed | – | – | – |
| Aug 2002 | $1.27M | Seed | – | – | – |
3 investors in total: 3 institutional.
Investors in ProteoGenix
ProteoGenix has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include TPG, New Leaf Venture Partners and Burrill and Company.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Stage-agnostic investments in US life sciences are managed. | 2005 | nlvpartners.com | New York, United States | |
Fund of funds focused on pre-seed and seed-stage companies | 1992 | tpg.com | Fort Worth, United States | |
Multi-category products are listed on an online B2B platform. | 1994 | burrillandco.com | Wuxi, China |
Investor details for ProteoGenix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of ProteoGenix
3 dated milestones of ProteoGenix across 8 years, from founding to its latest funding, stage changes and deals.
- Funding First funding round of $1.3M.
- Founded ProteoGenix is founded.
- Funding Latest funding round, Debt – Conventional, of $4.0M.
Competitors of ProteoGenix
ProteoGenix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Amyris, Syngenta, AskBio, Somalogic and Ginkgo Bioworks, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| amyris.com | 2003 | Emeryville, United States | $487.2M | 747 | Developer of renewable products for industrial solutions | |
| syngenta.com | 2000 | Basel, Switzerland | – | – | Crop protection solutions and hybrid seeds are provided for farming. | |
| askbio.com | 2001 | Durham, United States | $235M | – | Gene and protein therapies are developed for treating various diseases. | |
| somalogic.com | 1999 | Boulder, United States | $663.99M | 319 | Protein-based assays are developed for life science research. | |
| ginkgobioworks.com | 2008 | Boston, United States | $795.75M | 1,218 | Gene editing-based cultured ingredients are provided for agriculture. | |
| nautilus.bio | 2016 | Seattle, United States | $103.26M | 134 | A proteomics platform is developed for analyzing the human proteome. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| twistbioscience.com | 2013 | San Francisco, United States | $245.81M | 919 | Synthetic DNA is synthesized via a semiconductor-based platform. | |
| asimov.com | 2017 | Boston, United States | $209.4M | 87 | Provider of integrated suite for advanced genetic design and manufacturing |
Detailed competitors of ProteoGenix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ProteoGenix
The website of ProteoGenix (proteogenix.science) receives about 26.4K visits a month.
- Monthly visits26.4K
▲ 20.7% vs previous month
Websites whose visitors overlap most with ProteoGenix. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
antibodysystem.com | antibodysystem.com | 100% | – | #1,580,391 | – |
| cellsciences.com | 97% | 10.9K | #2,226,810 | View details | |
targetmol.com | targetmol.com | 89% | – | #394,604 | – |
| eurogentec.com | 88% | 40.4K | #771,641 | View details | |
creativebiolabs.net | creativebiolabs.net | 86% | – | #1,184,982 | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for ProteoGenix
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Proteogenix
Complete news archive for ProteoGenix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to ProteoGenix
10 companies that operate in the same segment as ProteoGenix (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about ProteoGenix
ProteoGenix was founded in 2003.
ProteoGenix is headquartered in Schiltigheim, France. It is registered at Schiltigheim, Grand Est, France.
ProteoGenix is a funded company, having raised a total of $35.23M across 8 funding rounds to date. The company's 1st funding round was a Seed of $1.27M, raised on Aug 2002.
ProteoGenix has 7 employees.
ProteoGenix is a company offering custom synthesis services for Proteins (in E. Coli, yeast, insect cells (baculovirus) and mammalian cells), Peptides (including Purification and Conjugation), Monoclonal and Polyclonal antibody production, Gene synthesis (including sub-cloning and mutagenesis). They also offer analytical services to study DNA-Protein interactions (through their yeast One-Hybrid system) and for applications such as DNA and RNA purification, ELISA Assays, Immunoprecipitation, PCR and qPCR. The company also offers ELISA kits, tissue microarrays, chimera RNAi, molecular biology products and several other products for research and academic communities.
ProteoGenix offers Custom Antibody Development, Custom Protein Expression, Peptide Synthesis, and XtenCHO Race Starter Kit.
ProteoGenix has 3 investors. Key investors include TPG, New Leaf Venture Partners, and Burrill and Company.
ProteoGenix operates through Proteogenex, Inc..